The organic nitrate NDBP promotes cardiometabolic protection in type 1 diabetic mice

Abstract

Studies from our laboratory have shown that the nitric oxide (NO) donor 2-nitrate-1,3-dibutoxypropan (NDBP) lowers blood pressure in hypertension. However, the role of NDBP in other cardiometabolic diseases such as diabetes remains unknown. Our study aimed to evaluate the cardiometabolic effect of NDBP treatment in type 1 diabetes (T1DM) mice. T1DM was induced by streptozotocin (i.p. 50 mg/kg, 5 days) and confirmed by fasting glucose (≥200 mg/dL). Following induction of T1DM, mice were treated with NDBP (40 mg/kg/day i.p.) or vehicle (cremophor in saline) for 14 days. Our data revealed that NDBP treatment in T1DM mice reduced hyperglycemia, water consumption, urine volume, and oxidative stress in the liver and pancreas and increased glucose tolerance. Furthermore, NDBP treatment improved vascular function, although it was not able to attenuate hypertension. In conclusion, our study results indicate that NDBP promotes beneficial metabolic effects and improves endothelium-independent vascular function in a mouse model of T1DM.

Keywords

• Diabetes
• Nitric oxide
• Aorta
• Blood pressure